MoneyThe story, in brief
Helical raises $10M to bridge the gap between foundation models and drug discovery decisions
$10M. That's what Helical just raised to turn biological foundation models into drug discovery workflows.
The KeyNews take
Why it matters
A pharma AI startup is closing the commercialization gap between foundation models and real-world drug discovery decisions—signaling investor confidence in AI-native biotech and the shift from model capability to application velocity.
The key facts
5 to knowHelical Ltd. raised $10M in funding
Founded in 2024
Focus: biological foundation models → in-silico drug discovery workflows
Use case: pharma AI/drug discovery
Company mission: bridge foundation models to reproducible, decision-ready workflows
Go to the source
SiliconAnglesiliconangle.com
Publisher excerpt: Pharma artificial intelligence startup Helical Ltd. announced today that it has raised $10 million in new funding to expand its virtual AI lab platform, which turns biological foundation models into reproducible in-silico drug discovery workflows. Founded in 2024, Helical was built around a…